Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tenax Therapeutics (TENX) Gains from Sales and Divestitures (2016 - 2019)

Tenax Therapeutics' Gains from Sales and Divestitures history spans 5 years, with the latest figure at $5838.0 for Q4 2017.

  • On a quarterly basis, Gains from Sales and Divestitures rose 36387.5% to $5838.0 in Q4 2017 year-over-year; TTM through Dec 2017 was $5838.0, a 36387.5% increase, with the full-year FY2017 number at $5838.0, up 36387.5% from a year prior.
  • Gains from Sales and Divestitures hit $5838.0 in Q4 2017 for Tenax Therapeutics, down from $116525.0 in the prior quarter.
  • Over the last five years, Gains from Sales and Divestitures for TENX hit a ceiling of $116525.0 in Q2 2017 and a floor of -$17700.0 in Q3 2014.
  • Historically, Gains from Sales and Divestitures has averaged $34104.7 across 5 years, with a median of $29796.0 in 2014.
  • Biggest five-year swings in Gains from Sales and Divestitures: plummeted 1378.9% in 2014 and later soared 151163.64% in 2017.
  • Tracing TENX's Gains from Sales and Divestitures over 5 years: stood at $50062.0 in 2013, then crashed by 40.48% to $29796.0 in 2014, then tumbled by 99.42% to $174.0 in 2015, then crashed by 90.8% to $16.0 in 2016, then skyrocketed by 36387.5% to $5838.0 in 2017.
  • Business Quant data shows Gains from Sales and Divestitures for TENX at $5838.0 in Q4 2017, $116525.0 in Q3 2017, and $116525.0 in Q2 2017.